Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enveric Biosciences, Inc. - Common Stock (NQ: ENVB )

1.600 +0.010 (+0.63%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Enveric Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Enveric Biosciences Inks Two Licensing Agreements With Restoration Biologics To Treat Joint Disease
Enveric's Akos Biosciences licensed its cannabinoid-COX-2 conjugate technology to Restoration Biologics for joint disease treatments, including osteoarthritis. 
Via Benzinga
What's going on in today's session
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Dow Edges Lower; Exxon Mobil Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Which stocks are gapping on Friday?
The market is buzzing with gapping stocks on Friday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
Why Is Enveric Biosciences (ENVB) Stock Up 18% Today?
Enveric Biosciences stock is up on Tuesday with heavy trading of ENVB shares despite a lack of news from the company this morning. 
Via InvestorPlace
Nasdaq Jumps Over 150 Points; Apple Posts Upbeat Earnings
Via Benzinga
These stocks are moving in today's pre-market session
Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
What's going on in today's after hours session
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Let's take a look at the stocks that are in motion in today's session.
Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Here are the top movers in Wednesday's session.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Enveric Biosciences Advances Non-Hallucinogenic DMT Analog Drug With Promising Preclinical Results
Via Benzinga
Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Enveric Biosciences Trims Losses, Eyes Key Drug Approval For Difficult-To-Treat Mental Health Disorders
Via Benzinga
Enveric Biosciences Out-Licenses Key Program To MycoMedica In $62M Deal
Enveric licenses EB-002 to MycoMedica for neuropsychiatric treatment, focusing on EB-003's development with potential milestones up to $62M. 
Via Benzinga
Enveric Biosciences Expands Mental Health Patent Portfolio With 5 New Additions
Enveric Biosciences expands its patent portfolio with five new U.S. patents, supporting treatments for depression, anxiety and epilepsy. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Enveric Biosciences Advances Testing Of Its Non-Hallucinogenic Psychedelic
Enveric Biosciences announces positive preclinical results for EB-003, showcasing its potential as a safe and effective treatment for mental health disorders. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies
Companies are developing safer, targeted psychedelic therapies aimed at reducing risks and improving mental health treatment options. 
Via Benzinga
Non-Hallucinogenic Psychedelic Treatment For Anxiety And Depression In Pre-Clinical Models: Enveric Biosciences' Breakthrough Research
Psychedelics biotech company Enveric Biosciences (NASDAQ: ENVB) has presented research highlighting the company's lead compound, EB-003 at the 7th Neuropsychiatric Drug Summit. The conference is being... 
Via Benzinga
ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q2 2024
ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Why Is Imunon (IMNN) Stock Up 259% Today?
Imunon stock is up on Tuesday with heavy trading of IMNN shares after posting positive results from a Phase 2 clinical trial. 
Via InvestorPlace
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Is Ekso Bionics (EKSO) Stock Down 15% Today?
Ekso Bionics stock is down on Tuesday as investors in the company react to its lackluster earnings report for the second quarter of the year. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are a hot topic as we jump into all of the biggest news that has shares heading higher and lower on Tuesday morning! 
Via InvestorPlace
Why F5 Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.